Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for $1,500,000 over 2 years to support the modification of their proprietary Total Holographic Characterization® technology to meet the specific needs of the biologics pharmaceutical industry.
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization® of colloidal materials. Spheryx’s proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials’ characteristics. Applications include R&D, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs.
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially.